Constellation Brands, Inc.
Constellation Brands Announces Full Redemption of 3.75% Senior Notes Due 2021
VICTOR, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) --
Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it has given notice for full redemption prior to maturity of all of its outstanding 3.75% Senior Notes due 2021 (CUSIP Number: 21036PAK4) (the "notes") to be effected on February 4, 2021 (the "redemption date"). As of January 5, 2021, there were $500.0 million in aggregate principal amount of the notes outstanding.
The redemption price for the notes, payable in cash, will be calculated pursuant to the formula set forth in the supplemental indenture relating to the notes, and will include a make-whole premium of approximately $4.0 million.
ABOUT CONSTELLATION BRANDS
Constellation Brands is an international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Constellation is the third-largest beer company in the U.S. and a leading, higher-end wine and spirits company in the U.S. market. Constellation’s brand portfolio includes Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, Pacifico, the Robert Mondavi brand family, Kim Crawford, Meiomi, The Prisoner brand family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Statements which are not historical facts and relate to future plans, events or performance are forward-looking statements that are based upon management’s current expectations and are subject to risks and uncertainties. The forward-looking statements are based on management's current expectations and should not be construed in any manner as a guarantee that such events or results will in fact occur. All forward-looking statements speak only as of the date of this news release and Constellation Brands undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Detailed information regarding risk factors with respect to the company are included in the company’s filings with the SEC.
|MEDIA CONTACTS||INVESTOR RELATIONS CONTACTS|
|Mike McGrew 773-251-4934 / firstname.lastname@example.org
Amy Martin 585-678-7141 / email@example.com
|Patty Yahn-Urlaub 585-678-7483 / firstname.lastname@example.org
Marisa Pepelea 312-741-2316 / email@example.com
A downloadable PDF copy of this news release can be found here: http://ml.globenewswire.com/Resource/Download/52a4a6a8-efdf-42f2-80fb-c52140c421ba
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Karolinska Development AB (publ)26.1.2021 13:48:38 CET | Press release
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
Mandalay Resources Corporation26.1.2021 13:31:27 CET | Press release
Mandalay Resources Corporation Announces Recent Drilling Results for Costerfield’s Youle Deposit, Highlighting Further High-Grade Gold Depth Extensions
Cemat A/S26.1.2021 13:07:16 CET | Press release
No. 1/2021 - Financial calendar 2021/2022
Cemat A/S26.1.2021 13:07:06 CET | Pressemeddelelse
Nr. 1/2021 - Finanskalender 2021/2022
Intelex Technologies, ULC26.1.2021 13:06:23 CET | Press release
INTELEX SECURES UNINTERRUPTED POSITION AS A LEADER IN GREEN QUADRANT FOR EHS SOFTWARE 2021
Chr. Hansen Holding A/S26.1.2021 13:04:13 CET | Press release
Allarity Therapeutics A/S26.1.2021 13:01:22 CET | Press release
Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom